Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Avantor's recent quarterly earnings report provides a mixed view of the company's current performance and strategic outlook.</li><li>Avantor experienced a 5% decline in quarterly revenue year-over-year, with reported revenue of $1.62 billion.</li><li>The decline primarily affects the Laboratory Solutions and Bioscience Production segments.</li></ul>

Avantor's recent quarterly earnings report provides a mixed view of the company's current performance and strategic outlook.Avantor experienced a 5% decline in quarterly revenue year-over-year, with reported revenue of $1.62 billion.The decline primarily affects the Laboratory Solutions and Bioscience Production segments.

Avantor: Bioprocessing Innovation in Sterile Sampling & Other Key Growth Levers!

<ul><li>Avantor, the $7.8 billion life sciences supplier headquartered in Radnor, Pennsylvania, has recently drawn the attention of activist investor Engine Capital, which has taken a roughly 3% stake in the company.</li><li>The move comes after a tumultuous year in which Avantor’s shares fell nearly 50%, pressured by weakened demand—especially in government and education sectors due to research funding cuts—and the April announcement of its longtime CEO’s departure.</li><li>Now, with a new chief executive, Emmanuel Ligner, set to take the helm in mid-August, Engine Capital is urging Avantor to either sell itself outright or embark on a strategic overhaul that could include a board refresh, cost reductions, stock buybacks, and divestitures of noncore assets.</li></ul>

Avantor, the $7.8 billion life sciences supplier headquartered in Radnor, Pennsylvania, has recently drawn the attention of activist investor Engine Capital, which has taken a roughly 3% stake in the company.The move comes after a tumultuous year in which Avantor’s shares fell nearly 50%, pressured by weakened demand—especially in government and education sectors due to research funding cuts—and the April announcement of its longtime CEO’s departure.Now, with a new chief executive, Emmanuel Ligner, set to take the helm in mid-August, Engine Capital is urging Avantor to either sell itself outright or embark on a strategic overhaul that could include a board refresh, cost reductions, stock buybacks, and divestitures of noncore assets.

Avantor Faces Activist Fire: Why Engine Capital Wants It Sold Now?

<ul><li>Avantor's first-quarter 2025 earnings results reveal both challenges and strategic initiatives that frame a complex investment landscape for the company.</li><li>Avantor reported an organic revenue decline of 2% year-over-year, signaling underperformance primarily within its Lab Solutions segment.</li><li>Despite this, the company managed to maintain an adjusted EBITDA margin of 17%, a 20 basis point increase from the prior year.</li></ul>

Avantor's first-quarter 2025 earnings results reveal both challenges and strategic initiatives that frame a complex investment landscape for the company.Avantor reported an organic revenue decline of 2% year-over-year, signaling underperformance primarily within its Lab Solutions segment.Despite this, the company managed to maintain an adjusted EBITDA margin of 17%, a 20 basis point increase from the prior year.

Avantor’s Bioprocessing Boom: Is This Billion Dollar Platform The Key To Outsized Growth?

<ul><li>Avantor, a global supplier of materials and services for the life sciences and advanced technology industries, reported its fourth-quarter 2024 financial results, indicating a mix of positive and challenging elements in its performance.</li><li>Avantor noted a return to low single-digit organic growth across the enterprise, a milestone that aligns with the broader market recovery.</li><li>The bioprocessing business, in particular, showed strong performance for a fourth consecutive quarter, achieving high single-digit organic growth.</li></ul>

Avantor, a global supplier of materials and services for the life sciences and advanced technology industries, reported its fourth-quarter 2024 financial results, indicating a mix of positive and challenging elements in its performance.Avantor noted a return to low single-digit organic growth across the enterprise, a milestone that aligns with the broader market recovery.The bioprocessing business, in particular, showed strong performance for a fourth consecutive quarter, achieving high single-digit organic growth.

Avantor Inc.: 6 Major Game-Changers Impacting Its 2025 Performance & Beyond!

Alpha-Centric ESG Research

Kyle Rudden

COVID-19 vaccines figure into Biden's recently-announced COVID-19 response plan, though with a clear emphasis on distribution versus development (as was Trump's focus). Biden's prioritisation of vaccine distribution – and the US$25 billion earmarked for it – is a gift for "cold chain" stocks."Cold chain" refers to a complex temperature-controlled supply chain that is mission-critical to the distribution of COVID-19 vaccines. Critical, because vaccines require consistent ultra-cold storage from manufacture to needle-stick, otherwise those expensive vaccines become medical waste.This Insight looks at cold chain stocks as an investment theme inherent in Biden's COVID-19 plan (see <a href="https://www.smartkarma.com/insights/biden-covid-19-response-plan-overview-of-its-inherent-investment-themes" target="_blank" data-smartkarma-citation="insights:45631" rel="noopener">Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes</a>). Although the cold chain is fragmented and largely privately-held, but there are opportunities in three areas:<ol>
<li>
Freight and Logistics: Most listed companies fall into this category, including both integrated cold chain freight and logistics stocks, as well as niche players in either of freight or logistics.</li>
<li>
Freezer Manufacturers: Ultra-cold freezer boxes and related industrial components of various shapes and sizes are needed for the cold chain to function. Several stocks serve this segment.</li>
<li>
Specialty Chemicals: Dry ice gets all the headlines, as massive amounts are needed but supply is short, but other specialty chemicals and industrial gases are also needed in the cold chain.</li>
</ol>

COVID-19 vaccines figure into Biden's recently-announced COVID-19 response plan, though with a clear emphasis on distribution versus development (as was Trump's focus). Biden's prioritisation of vaccine distribution – and the US$25 billion earmarked for it – is a gift for "cold chain" stocks."Cold chain" refers to a complex temperature-controlled supply chain that is mission-critical to the distribution of COVID-19 vaccines. Critical, because vaccines require consistent ultra-cold storage from manufacture to needle-stick, otherwise those expensive vaccines become medical waste.This Insight looks at cold chain stocks as an investment theme inherent in Biden's COVID-19 plan (see Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes). Although the cold chain is fragmented and largely privately-held, but there are opportunities in three areas:

Freight and Logistics: Most listed companies fall into this category, including both integrated cold chain freight and logistics stocks, as well as niche players in either of freight or logistics.

Freezer Manufacturers: Ultra-cold freezer boxes and related industrial components of various shapes and sizes are needed for the cold chain to function. Several stocks serve this segment.

Specialty Chemicals: Dry ice gets all the headlines, as massive amounts are needed but supply is short, but other specialty chemicals and industrial gases are also needed in the cold chain.


Biden COVID-19 Response Plan: Cold Chain Transportation and Logistics Stocks Benefit

United States

Avantor, Inc. manufactures and distributes chemicals, reagents, and laboratory supplies. The Company offers amino acids, silicones, bioreagents, denaturants, gas, solvents, stains, dyes, and minerals. Avantor serves biopharma, healthcare, education and government, advanced technologies, life sciences, and applied materials industries worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avantor (AVTR US)

Avantor: Bioprocessing Innovation in Sterile Sampling & Other Key Growth Levers!

Avantor's recent quarterly earnings report provides a mixed view of the company's current performance and strategic outlook. Avantor experienced a...

Baptista Research

Avantor Faces Activist Fire: Why Engine Capital Wants It Sold Now?

Avantor, the $7.8 billion life sciences supplier headquartered in Radnor, Pennsylvania, has recently drawn the attention of activist investor...

Baptista Research

Avantor’s Bioprocessing Boom: Is This Billion Dollar Platform The Key To Outsized Growth?

Avantor's first-quarter 2025 earnings results reveal both challenges and strategic initiatives that frame a complex investment landscape for the...

Baptista Research

Avantor Inc.: 6 Major Game-Changers Impacting Its 2025 Performance & Beyond!

Avantor, a global supplier of materials and services for the life sciences and advanced technology industries, reported its fourth-quarter 2024...

Baptista Research

Biden COVID-19 Response Plan: Cold Chain Transportation and Logistics Stocks Benefit

Biden's COVID-19 response plan earmarks US$25 billion to vaccines, but with a twist. His emphasis is vaccine distribution, not development. That...

Kyle Rudden

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)